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background: In the PLATINUM randomized controlled trial, the PROMUS Element Everolimus Eluting Stent (PtCr-EES) was non-inferior to the 
cobalt chromium PROMUS/XIENCE V EES (CoCr-EES) for the primary endpoint of target lesion failure (TLF) at 1 year. Although the stents have similar 
polymer, drug and drug concentration, they differ in metal alloy composition and design with consequent differences in flexibility/conformability and 
target lesion/vessel geometric distortion. Whether these specific stent attributes confer objective clinical benefit over time is unknown.
Methods: Patients (N=1,530) with 1 or 2 de novo native coronary artery lesions (baseline vessel diameter ≥2.50 mm to ≤4.25 mm and lesion 
length ≤24 mm) were randomized 1:1 to PtCr-EES versus CoCr-EES. Exclusion criteria included acute or recent myocardial infarction (MI), left 
ventricular ejection fraction <30%, left main or ostial location, bifurcation disease, CTO, and target vessel thrombus. Routine angiographic follow-up 
was not performed.
results: Baseline demographics were comparable between randomized study groups. Unplanned (bailout) stenting was more frequent with CoCr-
EES than with PtCr-EES (9.8% vs 5.9%; P=0.004). Previously reported 3-year results demonstrated no significant differences between CoCr-EES and 
PtCr-EES in all-cause mortality (4.3% vs. 3.7% respectively; P=0.62), myocardial infarction (2.5% vs. 2.3%; P=0.81), target lesion revascularization 
(4.9% vs. 3.5%; P=0.21), target lesion failure (7.1% vs 5.9%; P=0.40) or ARC definite/probable stent thrombosis (0.5% vs 0.7%; P=0.76). Landmark 
analyses previously demonstrated significant differences in TLF (HR 0.44 [95% CI 0.20, 0.97]; P=0.04) and ischemic driven TLR (0.33 [0.12, 0.90]; 
P=0.02) at 2 years, although statistical significance was lost at the 3-year follow-up (0.68 [0.39, 1.18]; P=0.17, and 0.61 [0.31, 1.20]; P=0.15, 
respectively).
conclusions: Overall 3-year outcomes were comparable between PtCr-EES and CoCr-EES. Complete 4-year follow-up will be presented, including 
ongoing evaluation of the landmark analyses, and may provide further insights into the relationship between stent platform design and late clinical 
outcomes.
